In the Q2, Agile Therapeutics Inc's corporate clients experienced a reduction by -2.38 % in their costs of revenue, compared to a year ago, sequentially costs of revenue grew by 2.41 %. During the corresponding time, Agile Therapeutics Inc saw a revenue deteriorated by -2.23 % year on year, sequentially revenue grew by 0.87 %. While revenue at the Agile Therapeutics Inc's corporate clients recorded rose by 2.63 % year on year, sequentially revenue grew by 1.78 %.
Customers of Agile Therapeutics Inc saw their costs of revenue decrease by -2.38 % in Q2 compare to a year ago, sequentially costs of revenue grew by 2.41 %, for the same period Agile Therapeutics Inc revnue deteriorated by -2.23 % year on year, sequentially revenue grew by 0.87 %.
Agile Therapeutics Inc's Comment on Sales, Marketing and Customers
The company targets consumers and commercial managed care plans. In 2024, its marketing efforts focus on females aged 18 to 24 who are highly engaged online and seek health information through digital media and social networks. Marketing tactics are optimized for mobile technology and include digital media, social media advertising, video, and mass-market advertising to generate awareness and demand for Twirla. Following FDA approval of Twirla, the company engaged with formulary decision makers to secure access, achieving coverage for approximately 55-60% of covered lives by commercial third-party payors. The company plans to expand formulary access through contracting strategies and engagement with formulary boards. Its pipeline includes a progestin-only contraceptive patch (P-Patch) intended for women unable or unwilling to take estrogen, including breastfeeding women and those at greater risk of venous thromboembolism (VTE), such as smokers, women over 35, or those with a BMI over 30 kg/m2. The progestin-only market currently consists of pills and several non-daily options.
Furthermore, Agile Therapeutics corporate customers have recorded a significant increase in their cost of revenue by 6.84% in the third quarter of 2023 year on year, with sequential costs of revenue growing by 1.9%. Meanwhile, Agile Therapeutics Inc. achieved an impressive revenue increase of 106.03% year on year, with sequential revenue growth of 19.03%. The revenue at Agile Therapeutics Inc. s corporate clients also saw a rise of 8.57% year on year, with sequential revenue growth of 0.57%. These fluctuations in revenue and costs indicate that the company is experiencing increased expenses and decreased investment and spending from its corporate customers.To gain insight into the outlook of consumer spendi...
Agile Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company targets consumers and commercial managed care plans. In 2024, its marketing efforts focus on females aged 18 to 24 who are highly engaged online and seek health information through digital media and social networks. Marketing tactics are optimized for mobile technology and include digital media, social media advertising, video, and mass-market advertising to generate awareness and demand for Twirla. Following FDA approval of Twirla, the company engaged with formulary decision makers to secure access, achieving coverage for approximately 55-60% of covered lives by commercial third-party payors. The company plans to expand formulary access through contracting strategies and engagement with formulary boards. Its pipeline includes a progestin-only contraceptive patch (P-Patch) intended for women unable or unwilling to take estrogen, including breastfeeding women and those at greater risk of venous thromboembolism (VTE), such as smokers, women over 35, or those with a BMI over 30 kg/m2. The progestin-only market currently consists of pills and several non-daily options.
Sources:
Agile Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Agile Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Agile Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
36.14 % 